Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Activation of hepatic thyroid hormone receptor β (THR‐β) is associated with systemic lipid lowering, increased bile acid synthesis, and fat oxidation. In patients with non‐alcoholic steatohepatitis (NASH), treatment with THR‐β agonists decreased hepatic steatosis and circulating lipids, and induced resolution of NASH. We chose resmetirom (MGL‐3196), a liver‐directed, selective THR‐β agonist, as a prototype to investigate the effects of THR‐β activation in mice with diet‐induced obesity (DIO) and biopsy‐confirmed advanced NASH with fibrosis. Experimental Approach: C57Bl/6J mice were fed a diet high in fat, fructose, and cholesterol for 34 weeks, and only biopsy‐confirmed DIO‐NASH mice with fibrosis were included. Resmetirom was administered at a daily dose of 3 mg·kg−1 p.o., for 8 weeks. Systemic and hepatic metabolic parameters, histological non‐alcoholic fatty liver disease (NAFLD) activity and fibrosis scores, and liver RNA expression profiles were determined to assess the effect of THR‐β activation. Key Results: Treatment with resmetirom did not influence body weight but led to significant reduction in liver weight, hepatic steatosis, plasma alanine aminotransferase activity, liver and plasma cholesterol, and blood glucose. These metabolic effects translated into significant improvement in NAFLD activity score. Moreover, a lower content of α‐smooth muscle actin and down‐regulation of genes involved in fibrogenesis indicated a decrease in hepatic fibrosis. Conclusion and Implications: Our model robustly reflected clinical observations of body weight‐independent improvements in systemic and hepatic metabolism including anti‐steatotic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 1×
“intervention with a focus on weight loss (Chalasani et al., 2018).”
BackgroundA Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000410 · Cited by 5,939
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 2×
“The prevalence of NASH is increasing (Estes, Anstee, et al., 2018; Estes, Razavi, et al., 2018), and NASH with advanced fibrosis is associated with a strong increase in liver-related and overall mortality (Dulai et al., 2017; Ekstedt et al., 2015).”
BackgroundDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 2×
“The prevalence of NASH is increasing (Estes, Anstee, et al., 2018; Estes, Razavi, et al., 2018), and NASH with advanced fibrosis is associated with a strong increase in liver-related and overall mortality (Dulai et al., 2017; Ekstedt et al., 2015).”
BackgroundCurtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14153 · Cited by 1,338 · cited 1×
“The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et al., 2018).”
MethodCause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283 · cited 1×
“NASH is characterized by marked hepatic steatosis, lobular inflammation and hepatocyte ballooning (Diehl & Day, 2017).”
BackgroundYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P. H., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15178 · Cited by 1,214
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Clapper, J. R., Hendricks, M. D., Gu, G., Wittmer, C., Dolman, C. S., Herich, J., Athanacio, J., Villescaz, C., Ghosh, S. S., Heilig, J. S., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00079.2013 · Cited by 294 · cited 2×
“…ad libitum access for 34 weeks to a regular rodent diet (n = 12; Altromin 1324) or a diet high in fat (40%), of these 18% trans-fat, 40% carbohydrates (20% fructose), and 2% cholesterol (n = 24; ) previously described as the Amylin Liver NASH diet (AMLN diet) (Clapper et al., 2013) and tap water.”
MethodKelly, M. J., Pietranico-Cole, S., Larigan, J. D., Haynes, N.-E., Reynolds, C. H., Scott, N., Vermeulen, J., Dvorozniak, M., Conde-Knape, K., Huang, K.-S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4019299 · Cited by 231
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Kannt, A., Madsen, A. N., Kammermeier, C., Elvert, R., Klöckener, T., Bossart, M., Haack, T., Evers, A., Lorenz, K., Hennerici, W., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14035 · Cited by 37 · cited 1×
“Thus, the 8-week treatment schedule in our study, chosen on the basis of previous studies in the same model with different types of intervention (Kannt et al., 2019, 2020; Tølbøl et al., 2018) may have been too short for a significant improvement in fibrosis score.”
MethodSelf-citation
Cited by
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Keam, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02045-0 · Cited by 355
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“The most advanced compound, resmetirom (MGL-3196), has demonstrated robust antisteatotic activity in preclinical models of NAFLD [112].”
Background
Metadata
- Authors
- Kannt, A., Wohlfart, P., Madsen, A. N., Veidal, S. S., Feigh, M., & Schmoll, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2021-04-06
- Volume
- 178
- Issue
- 12
- Pages
- 2412-2423
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3133899324
- Cited by
- 139
- References
- 16
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.